Discover more insights into Sglt2 Inhibition Sglt2 억제

Keywords frequently search together with Sglt2 Inhibition Sglt2 억제

Narrow sentence examples with built-in keyword filters

Sglt2 Inhibition sentence examples within chronic kidney disease



A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.


Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease

Sglt2 Inhibition sentence examples within Pharmacological Sglt2 Inhibition



Renal SGLT mRNA Expression in Human Health and Disease: A Study in Two Cohorts.


Vertical sleeve gastrectomy lowers kidney SGLT2 expression in the mouse

Sglt2 Inhibition sentence examples within sglt2 inhibition cause



Renal effects of SGLT2 inhibitors: an update.


155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion


Learn more from Sglt2 Inhibition Sglt2 억제


Sglt2 Inhibition sentence examples within sglt2 inhibition significantly



SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.


Urinary glucose excretion contributions of SGLT2 vs. SGLT1 transporters: a quantitative systems pharmacology analysis in healthy and T2DM subjects administered SGLT2 inhibitors.

Sglt2 Inhibition sentence examples within sglt2 inhibition reduce



Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload


Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes

Sglt2 Inhibition sentence examples within sglt2 inhibition restore



Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Down Regulation of sGC and Contributes to Exercise-Induced Pulmonary Hypertension in HFpEF.


Metabolic Syndrome Mediates ROS-miR-193b-NFYA–Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction

Sglt2 Inhibition sentence examples within sglt2 inhibition increase



Sodium glucose transporter inhibition in heart failure From an unexpected side effect to a novel treatment possibility.


Response to: Correspondence on “Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure” by Yalta et al

Sglt2 Inhibition sentence examples within sglt2 inhibition remain



Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations


Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice


Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage



Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation.


More Sglt2 Inhibition Sglt2 억제 sentence examples
10.1146/annurev-pharmtox-052120-014725

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.



Sex-Specific Computational Models of Kidney Function in Patients with Diabetes



SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis



Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis



Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/SIRT1 Pathway.



Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.



Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial


More Sglt2 Inhibition Sglt2 억제 sentence examples
10.1016/j.pharmthera.2021.107832

Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors.



Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function



Heart failure drug treatment: the fantastic four



Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus



Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial



Effects of SGLT2 inhibitor on ischemic events stemming from atherosclerotic coronary diseases: A systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.



Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.



Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice



Dapagliflozin Exerts Adrenal Sympatholysis via G protein-Coupled Receptor Kinase-2 & Tyrosine Hydroxylase Downregulation



SGLT2 Inhibition by Canagliflozin Ameliorates Diet-induced Obesity by Promoting Intra-adipose Sympathetic innervation.



What Does SGLT2 Inhibition Add in Managing Hyponatremia Secondary to Syndrome of Inappropriate Antidiuresis (SIAD)?



Effects of SGLT2 Inhibitor and Dietary NaCl on Glomerular Hemodynamics Assessed by Micropuncture in Diabetic Rats.



Effects of Empagliflozin on Erythropoiesis in Patients with Type 2 Diabetes - data from a randomized, placebo controlled study.



Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease



High glucose–induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model



The role of parasympathetic mechanisms in the infarct-limiting effect of SGLT2 inhibitor ertugliflozin



Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.



Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015



A Computational Model of Kidney Function in a Patient with Diabetes



SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot



781-P: Beyond Glucosuria: Urine Metabolome Signature Associated with Dapagliflozin in Wild-Type Mice



Do sodium‐glucose co‐transporter‐2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?



Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes



Sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in rats after cardiac arrest



1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)



Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.



Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes



Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.



Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus



67-OR: Plasma Copeptin and Risk for Lower Extremity Amputation in People with Type 1 and Type 2 Diabetes


More Sglt2 Inhibition Sglt2 억제 sentence examples
10.1161/CIRCULATIONAHA.118.037418

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging.



SodiumGlucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis



Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibition



Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats



Design and optimization strategies for the development of new drugs that treat chronic kidney disease



Sodium-glucose cotransporter inhibitors: beyond glycaemic control



A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors



Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits



The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update



1128-P: SGLT2 Inhibition Increases Serum Copeptin in Adults with Type 1 Diabetes (T1D)



SGLT2 Inhibition Increases Serum Copeptin in Young Adults with Type 1 Diabetes.



Heart failure prevention with sodium‐glucose cotransporter 2 inhibitors



Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction


More Sglt2 Inhibition Sglt2 억제 sentence examples
10.1161/CIRCULATIONAHA.119.042375

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.



Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus



Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy



Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training



Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage



Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.



Knockout of Na-glucose-cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase-1 in macula densa and glomerular hyperfiltration



Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats



Further insights into cardiovascular outcomes in diabetic and non-diabetic states: inhibition of sodium-glucose co-transports.


Sglt2 Inhibition Sglt2 억제


Sglt2 Inhibition Sglt2 억제
Encyclopedia 백과사전